A strong association between PD-L1 tumor expression and MMR deficiency has been documented in endometrial and colorectal carcinoma [43,44] and the efficacy of anti-PD-1/PD-L1 therapy has been shown to increase in MMR deficient tumors [16,45,46]. Here, CD274 is linked to colorectal carcinoma.